Literature DB >> 2416625

Early detection of hepatocellular carcinoma in patients with chronic type B hepatitis. A prospective study.

Y F Liaw, D I Tai, C M Chu, D Y Lin, I S Sheen, T J Chen, C C Pao.   

Abstract

A prospective surveillance of hepatocellular carcinoma (HCC) using serum alpha-fetoprotein and high-resolution, linear-array, real-time ultrasonography was carried out in 432 patients with clinicopathologically proven chronic type B hepatitis. During a follow-up period of 6-85 mo (median 23, mean 26.9 +/- 16.8 mo), asymptomatic HCC was identified in 8 patients, with a calculated annual incidence of 826/100,000, and 2768/100,000 for patients over age 35 yr. The relative risk of developing HCC in hepatitis B surface antigen-positive chronic hepatitis patients was 2 when compared to those that were hepatitis B surface antigen-negative, and was 5 when compared in patients over age 35 yr. Hepatocellular carcinomas detected by these methods were in a relatively early stage as most tumors were small, only 50% were associated with cirrhosis, 37.5% were positive for hepatitis B e antibody, and most were still resectable. We, therefore, recommend a combination of alpha-fetoprotein and ultrasonography surveillance in patients with chronic hepatitis in order to improve the chance of early HCC detection as well as the chance for successful resection. In addition, the low incidence of cirrhosis and hepatitis B e antibody in these patients with "early" HCCs and the occurrence of hepatitis B e antigen/hepatitis B e antibody seroconversion after HCC had developed suggest that the development of HCC and progression from hepatitis to cirrhosis were two independent (though related) sequelae of chronic hepatitis B virus infection.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2416625     DOI: 10.1016/0016-5085(86)90919-4

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  63 in total

1.  A randomized controlled clinical trial on the treatment of Thymosin a1 versus interferon-alpha in patients with hepatitis B.

Authors:  J You; L Zhuang; B Z Tang; W B Yang; S Y Ding; W Li; R X Wu; H L Zhang; Y M Zhang; S M Yan; L Zhang
Journal:  World J Gastroenterol       Date:  2001-06       Impact factor: 5.742

2.  Cost-effectiveness analysis of prophylactic lamivudine use in preventing vertical transmission of hepatitis B virus infection.

Authors:  Hui-Fang Hung; Hsiu-Hsi Chen
Journal:  Pharmacoeconomics       Date:  2011-12       Impact factor: 4.981

3.  Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults.

Authors:  S D Ryder
Journal:  Gut       Date:  2003-05       Impact factor: 23.059

4.  Prediction of the prognosis of liver cirrhosis in Japanese using Cox's proportional hazard model.

Authors:  Y Tsuji; S Koga; H Ibayashi; Y Nose; K Akazawa
Journal:  Gastroenterol Jpn       Date:  1987-10

5.  Efficacy of thymosin alpha-1 and interferon alpha in treatment of chronic viral hepatitis B: a randomized controlled study.

Authors:  Jing You; Lin Zhuang; Hong-Ying Cheng; Shou-Ming Yan; Lan Yu; Jun-Hua Huang; Bao-Zhang Tang; Meng-Ling Huang; Yong-Liang Ma; Virasakdi Chongsuvivatwong; Hutcha Sriplung; Alan Geater; Yan-Wei Qiao; Rong-Xue Wu
Journal:  World J Gastroenterol       Date:  2006-11-07       Impact factor: 5.742

6.  HBV-DNA-related hepatocellular carcinoma occurring in childhood. Report of three cases.

Authors:  R Giacchino; C Navone; F Facco; G Giambartolomei; P Pontisso; F Callea
Journal:  Dig Dis Sci       Date:  1991-08       Impact factor: 3.199

Review 7.  Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis.

Authors:  Asmaa-Ibrahim Gomaa; Shahid-A Khan; Mireille-B Toledano; Imam Waked; Simon-D Taylor-Robinson
Journal:  World J Gastroenterol       Date:  2008-07-21       Impact factor: 5.742

8.  Natural course following the onset of cirrhosis in patients with chronic hepatitis B: a long-term follow-up study.

Authors:  Yi-Cheng Chen; Chia-Ming Chu; Chau-Ting Yeh; Yun-Fan Liaw
Journal:  Hepatol Int       Date:  2007-03       Impact factor: 6.047

9.  Reappraisal of surgical treatment of small hepatocellular carcinomas in cirrhosis: clinicopathological study of resection or transplantation.

Authors:  L Belli; F Romani; L S Belli; L De Carlis; G Rondinara; F Baticci; E Del Favero; E Minola; F Donato; V Mazzaferro
Journal:  Dig Dis Sci       Date:  1989-10       Impact factor: 3.199

10.  Cytokeratin-19 fragments in serum (CYFRA 21-1) as a marker in primary liver cancer.

Authors:  T Uenishi; S Kubo; K Hirohashi; H Tanaka; T Shuto; T Yamamoto; S Nishiguchi
Journal:  Br J Cancer       Date:  2003-06-16       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.